Theresa Heggie has served as Freeline Chief Executive Officer and a member of its Board of Directors since June 1, 2020. Ms. Heggie is an accomplished rare disease leader and has a broad experience in rare diseases, a deep understanding of medicines for genetic diseases and direct experience in some of the indications Freeline is pursuing. Previously, she served as Senior Vice President, Head of CEMEA at Alnylam Pharmaceuticals from May 2017 to May 2020. Before Alnylam, Ms. Heggie had roles at Bupa Group until 2016 and at Shire plc, including Global Head of Commercial for its rare disease business and CEO of Jerini AG after its acquisition by Shire in 2008. Prior to joining Shire, she held a variety of positions at Baxter Healthcare and Janssen Pharmaceuticals. She also serves on the boards of directors of BioCryst Pharmaceuticals and ProQR Therapeutics. Ms. Heggie received a B.S. from Cornell University.